Efficacy of Adjuvant Tamsulosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial

Rafael Edgardo Maldonado-Valadez, Angel David Valdez-Vargas, José Antonio Alvarez, Edel Rafael Rodea-Montero, Rafael Edgardo Maldonado-Valadez, Angel David Valdez-Vargas, José Antonio Alvarez, Edel Rafael Rodea-Montero

Abstract

Introduction: Extracorporeal shock wave lithotripsy (ESWL) is an effective treatment for urolithiasis. Tamsulosin is capable of causing dilation and facilitating the migration of stones. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone-free rate after a single session of ESWL in the treatment of kidney stones.

Methods: This is a randomized, nonplacebo-controlled study with a sample of 60 adults with a single radiopaque kidney stone of 5-20 mm in diameter. After the ESWL session, the patients were divided into two groups. The control group received standard treatment for analgesia consisting of oral diclofenac (75 mg/12 h) as needed. The tamsulosin group received standard treatment for analgesia plus oral tamsulosin (0.4 mg/day) for eight weeks. In both groups, stone-free status was determined using a CT scan eight weeks after ESWL. The protocol of this study was registered with ClinicalTrials.gov, identifier: NCT04819828.

Results: Only 57 patients completed the study (28 tamsulosin and 29 control). Overall, the average stone diameter was 11.42 ± 4.52 mm. The stone-free rate was 50.88% (29 of 57) overall, 53.57% (15 of 28) for the tamsulosin group, and 48.27% (14 of 29) for the control group (p = 0.680). The estimated relative risk in favor of the tamsulosin group to achieve a stone-free status was 1.11 (95% CI 0.67-1.9). The estimated number needed to treat to achieve a single patient with renal stone-free status after eight weeks of ESWL adjuvant treatment with tamsulosin was 19.

Conclusion: Our findings suggest that tamsulosin as adjuvant treatment after a single ESWL session is well tolerated and safe, but it does not increase the stone-free rate in patients with a single radiopaque renal stone of 5-20 mm in diameter. Our results may support the use of tamsulosin with ESWL in the case of patients with a single radiopaque renal stone of 11-20 mm in diameter based on an apparent higher stone-free rate and a low rate of complications.

Conflict of interest statement

The authors declare no conflicts of interest.

Copyright © 2022 Rafael Edgardo Maldonado-Valadez et al.

Figures

Figure 1
Figure 1
CONSORT (Consolidated Standards of Reporting Clinical Trials) flow diagram of patient progress during the phases of the randomized trial.

References

    1. Pak C. Y. Kidney stones. The Lancet . 1998;351(9118):1797–1801. doi: 10.1016/s0140-6736(98)01295-1.
    1. Ramello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. Journal of Nephrology . 2000;3:S45–S50.
    1. Stamatelou K. K., Francis M. E., Jones C. A., Nyberg L. M., Curhan G. C. Time trends in reported prevalence of kidney stones in the United States: 1976-199411.See Editorial by Goldfarb, p. 1951. Kidney International . 2003;63(5):1817–1823. doi: 10.1046/j.1523-1755.2003.00917.x.
    1. Lingeman J. E., Coury T. A., Newman D. M., et al. Comparison of results and morbidity of percutaneous nephrostolithotomy and extracorporeal shock wave lithotripsy. The Journal of Urology . 1987;138(3):485–490. doi: 10.1016/s0022-5347(17)43236-8.
    1. Chaussy C., Brendel W., Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. The Lancet . 1980;316(8207):1265–1268. doi: 10.1016/s0140-6736(80)92335-1.
    1. Latifpour J., Kondo S., O’Hollaren B. Autonomic receptors in urinary tract: sex and age differences. Journal of Pharmacology and Experimental Therapeutics . 1990;253(2):661–667.
    1. Sitharamaiah K., Chalapathi G., Abdul Samad S. Role of deflazacort and tamsulosin in medical expulsive therapy for sympt O matic lower ureteric stones. Journal of Evolution of Medical and Dental Sciences . 2015;4(15):2499–2504.
    1. Richardson C. D., Donatucci C. F., Page S. O., Wilson K. H., Schwinn D. A. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned α1-adrenergic receptor subtypes. The Prostate . 1997;33(1):55–59. doi: 10.1002/(sici)1097-0045(19970915)33:1<55::aid-pros9>;2-8.
    1. Dellabella M., Milanese G., Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. The Journal of Urology . 2003;170(6 I):2202–2205. doi: 10.1097/01.ju.0000096050.22281.a7.
    1. Çervenàkov I., Fillo J., Mardiak J., Kopečnú M., Šmirala J., Labaš P. Speedy elimination of ureterolithiasis in lower part of ureters with the alpha 1-blocker-tamsulosin. International Urology and Nephrology . 2002;34(1):25–29. doi: 10.1023/a:1021368325512.
    1. Gravina G. L., Costa A. M., Ronchi P., et al. Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. Urology . 2005;66(1):24–28. doi: 10.1016/j.urology.2005.01.013.
    1. Vicentini F. C., Mazzucchi E., Brito A. H., Chedid Neto E. A., Danilovic A., Srougi M. Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology . 2011;78(5):1016–1021. doi: 10.1016/j.urology.2011.04.062.
    1. Hussein M. M. Does tamsulosin increase stone clearance after shockwave lithotripsy of renal stones? A prospective, randomized controlled study. Scandinavian Journal of Urology and Nephrology . 2010;44(1):27–31. doi: 10.3109/00365590903359916.
    1. Türk C., Knoll T., Petrik A., Sarica K., Seitz C., Straub M. Guidelines on Urolithiasis. 2010.
    1. Bhagat S. K., Chacko N. K., Kekre N. S., Gopalakrishnan G., Antonisamy B., Devasia A. Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi? The Journal of Urology . 2007;177(6):2185–2188. doi: 10.1016/j.juro.2007.01.160.
    1. Core Team R. A language and environment for statistical computing. 2019, .
    1. De Nunzio C., Brassetti A., Bellangino M., et al. Tamsulosin or silodosin adjuvant treatment is ineffective in improving shockwave lithotripsy outcome: a short-term follow-up randomized, placebo-controlled study. Journal of Endourology . 2016;30(7):817–821. doi: 10.1089/end.2016.0113.
    1. Ahmed A.-F., Shalaby E., El-Feky M., et al. Role of tamsulosin therapy after extracorporeal shockwave lithotripsy for renal stones: randomized controlled trial. Urologia Internationalis . 2016;97(3):266–272. doi: 10.1159/000445840.
    1. Zaytoun O. M., Yakoubi R., Zahran A. R. M., et al. Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial. Urological Research . 2012;40(4):327–332. doi: 10.1007/s00240-011-0410-x.
    1. Falahatkar S., Khosropanah I., Vajary A. D., Bateni Z. H., Khosropanah D., Allahkhah A. Is there a role for tamsulosin after shock wave lithotripsy in the treatment of renal and ureteral calculi? Journal of Endourology . 2011;25(3):495–498. doi: 10.1089/end.2010.0439.
    1. Naja V., Agarwal M. M., Mandal A. K., et al. Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. Urology . 2008;72(5):1006–1011. doi: 10.1016/j.urology.2008.05.035.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться